Clinical Efficacy and Safety of Bevacizumab, Apatinib, and Recombinant Human Endothelial Inhibitor in the Treatment of Advanced Gastric Cancer

Table 4

Comparison of quality of life scores among patients in the four groups (‾x ± s, points).

Groups	Physical functioning	Bodily pain	Social functioning	Role emotional	Mental health	Vitality	General health
Control group	69.31 ± 5.76	54.41 ± 4.35	49.87 ± 4.12	50.11 ± 5.64	61.87 ± 6.85	59.32 ± 7.13	65.97 ± 4.63
Study group I	79.11 ± 5.48	55.28 ± 5.79	53.46 ± 6.75	51.34 ± 4.97	70.55 ± 5.49	61.55 ± 6.82	78.11 ± 6.31
Study group II	83.57 ± 6.49	56.34 ± 5.91	54.51 ± 5.74	54.73 ± 5.17	74.66 ± 6.53	66.33 ± 7.28	78.94 ± 7.03
Study group III	80.42 ± 6.34	55.30 ± 3.36	53.36 ± 4.93	52.44 ± 4.23	74.32 ± 6.78	65.09 ± 4.87	77.57 ± 4.82
F							61.95
							0.279